Levolta Pharmaceuticals, Inc., an emerging company in developmental osteoarthritis (OA) therapy, was awarded a patent by the U.S. Patent and Trademark Office (USPTO) for its novel VOLT01, a derivative of zoledronic acid (ZA), a proposed commercial product that has shown promise as a disease-modifying drug in clinical trials. U.S. Patent 8,859,530 covers co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis. Formerly known as Voltarra Pharmaceuticals, Levolta’s pa...